INDIANAPOLIS, June 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month through LillyDirect's Self Pay Pharmacy Solutions and... Continue Reading
ATLANTA, GA, UNITED STATES, June 16, 2025 /EINPresswire.com/ -- ALYKA Health, a digital health company that partners with providers to empower patients to improve their cardiovascular health and outcomes, announced that it is now a supporting partner of the American Society for Preventive... Continue Reading
Despite advances in our knowledge and understanding of cardiovascular health, cardiovascular disease (CVD) remains the No. 1 killer of men and women in the United States. Continue Reading
Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, driven in large part by two modifiable risk factors: high blood pressure (hypertension) and high cholesterol (hypercholesterolemia). Continue Reading
TARRYTOWN, N.Y., June 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and commercial rights outside of... Continue Reading
TARRYTOWN, N.Y., June 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced interim results from the ongoing Phase 2 COURAGE trial investigating novel combinations of semaglutide (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or... Continue Reading
Even if you are well aware that heart disease is the leading killer of women, the fact that it’s responsible for one in three deaths is still a striking stat. But there’s hope: most cardiovascular disease is preventable, say top cardiologists. Continue Reading
INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and... Continue Reading
PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and... Continue Reading
THE WOODLANDS, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced topline results from the PROGRESS Phase 2b study evaluating pilavapadin (LX9211), an oral, non-opioid investigational adaptor-associated kinase 1 (AAK1) inhibitor in adult... Continue Reading
INDIANAPOLIS, Feb. 25, 2025 /PRNewswire/ -- Today Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also reduced the price of the 2.5 mg and 5 mg vials.... Continue Reading
New York, January 29, 2025We are pleased to announce an important update regarding Kaneka’s LIPOSORBER® LA-15 System Indications for clinically diagnosed Familial Hypercholesterolemic patients. As part of our ongoing commitment to advance patient care and support healthcare providers in... Continue Reading
